Viking Therapeutics Inc
VKTX26.980USD
+0.450+1.70%
Close 09/05, 16:00（ET）Quotes delayed by 15 min
3.03BMarket Cap
LossP/E TTM
More Details of Viking Therapeutics Inc Company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
Company Info
Ticker SymbolVKTX
Company nameViking Therapeutics Inc
IPO dateApr 29, 2015
CEODr. Brian W. Lian, Ph.D.
Number of employees36
Security typeOrdinary Share
Fiscal year-endApr 29
Address9920 Pacific Heights Blvd, Suite 350
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18587044660
Websitehttps://vikingtherapeutics.com/
Ticker SymbolVKTX
IPO dateApr 29, 2015
CEODr. Brian W. Lian, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Mr. J. Matthew Singleton, CPA
Mr. J. Matthew Singleton, CPA
Independent Director
Independent Director
--
--
Dr. Brian W. Lian, Ph.D.
Dr. Brian W. Lian, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.02%
Fidelity Management & Research Company LLC
6.78%
BlackRock Institutional Trust Company, N.A.
3.83%
State Street Global Advisors (US)
3.36%
JP Morgan Asset Management
2.24%
Other
74.78%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.02%
Fidelity Management & Research Company LLC
6.78%
BlackRock Institutional Trust Company, N.A.
3.83%
State Street Global Advisors (US)
3.36%
JP Morgan Asset Management
2.24%
Other
74.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.42%
Investment Advisor/Hedge Fund
13.66%
Hedge Fund
8.68%
Research Firm
4.71%
Individual Investor
2.15%
Sovereign Wealth Fund
1.57%
Pension Fund
0.72%
Family Office
0.53%
Bank and Trust
0.53%
Other
30.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
873
80.91M
71.95%
-19.10M
2025Q1
881
81.93M
72.95%
-19.61M
2024Q4
837
90.73M
82.19%
-16.87M
2024Q3
781
90.59M
82.61%
-15.25M
2024Q2
701
89.78M
82.34%
-10.20M
2024Q1
634
89.55M
82.55%
-7.02M
2023Q4
464
85.12M
85.96%
-16.14M
2023Q3
442
85.70M
86.63%
-10.01M
2023Q2
426
82.52M
83.46%
-982.32K
2023Q1
408
74.30M
93.67%
+22.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.14M
9.03%
-8.18K
-0.08%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.23M
9.11%
-6.28M
-38.05%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.87M
4.34%
+31.60K
+0.65%
Mar 31, 2025
State Street Global Advisors (US)
4.06M
3.61%
-870.07K
-17.66%
Mar 31, 2025
JP Morgan Asset Management
2.70M
2.41%
+664.27K
+32.59%
Mar 31, 2025
Fidelity Institutional Asset Management
1.02M
0.91%
+815.41K
+395.55%
Mar 31, 2025
Susquehanna International Group, LLP
1.68M
1.49%
+643.39K
+62.26%
Mar 31, 2025
Lian (Brian)
1.92M
1.71%
-446.09K
-18.85%
Mar 15, 2025
Geode Capital Management, L.L.C.
1.98M
1.77%
+103.68K
+5.51%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
JPMorgan Fundamental Data Science Small Core ETF
0.12%
JPMorgan Fundamental Data Science Mid Core ETF
0.08%
iShares Health Innovation Active ETF
0.06%
Avantis Inflation Focused Equity ETF
0.02%
First Trust NASDAQ Pharmaceuticals ETF
0%
Roundhill GLP-1 & Weight Loss ETF
0%
SPDR Russell 1000 Momentum Focus ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
Schwab U.S. Small-Cap ETF
0%
View more
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.12%
JPMorgan Fundamental Data Science Mid Core ETF
Proportion0.08%
iShares Health Innovation Active ETF
Proportion0.06%
Avantis Inflation Focused Equity ETF
Proportion0.02%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0%
Roundhill GLP-1 & Weight Loss ETF
Proportion0%
SPDR Russell 1000 Momentum Focus ETF
Proportion0%
Fidelity Small-Mid Multifactor ETF
Proportion0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
